Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Much of the research in optimizing anticoagulant therapy for acute VTE has been carried out in patients without malignancies. Given the aggressive natural history of VTE in cancer patients ...

Another anticoagulant available for thromboprophylaxis is fondaparinux, an indirect inhibitor of activated factor X. In a double-blind, non-inferiority trial of 2,927 patients undergoing high-risk ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

The number of patients under anticoagulation therapy is on the rise, and thereby, the demand for anticoagulants also increases. In 2022, 702,880 people died from heart disease, and such deaths ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic ...

Financing led by new Investors Fåhraeus Startup and Growth and EIC FundHELSINKI, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Aplagon, a ...

Age and hypertension are associated with increased risks for cranial ischemic complications in GCA, while anticoagulant therapy may offer protective benefits.

LOS ANGELES -- In the PRESTIGE-AF trial, survivors of intracerebral hemorrhage (ICH) had good protection against future ischemic events using direct oral anticoagulants (DOACs) -- though, as feared, ...

Venus Remedies has received marketing authorization from Indonesia for its Enoxaparin, an anticoagulant, in pre-filled syringes. The approval reinforces the company's presence in Southeast Asia and ...

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.